-
United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug
•
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement with Denmark’s Novo Nordisk A/S (NYSE: NVO). The deal grants Novo Nordisk global development, manufacturing, and commercialization rights to United Laboratories’ UBT251, excluding China mainland, Hong Kong, Macau, and Taiwan, where United Laboratories retains the…
-
Tonghua Dongbao Initiates Phase III Trial for Insulin Degludec, Liraglutide Combo in Type 2 Diabetes
•
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has initiated a Phase III clinical study for its insulin degludec and liraglutide combination drug, administering the first dose to a patient in China. This marks a significant step forward in the development of this biosimilar version of Novo Nordisk’s Xultophy. Drug Profile and…
-
NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient delivery option designed to provide cash-paying patients with all dose strengths of Wegovy at a reduced cost of USD 499 per month. Program DetailsThe introduction of NovoCare Pharmacy mirrors the approach taken by US major…
-
Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies
•
US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A/S (NYSE: NVO). The collaboration, combining Novo’s deep therapeutic knowledge and drug development experience with Gensaic’s novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates…
-
Tonghua Dongbao’s Tongboli Under GMP Inspection in Egypt
•
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection by the Ministry of Health of Egypt for its Tongboli, a biosimilar version of Novo Nordisk’s GLP-1 receptor agonist Victoza (liraglutide), is well underway in the country. Product BackgroundTongboli, the Victoza knockoff, received marketing approval…
-
Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities
•
Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business Division (EBD), is leaving the company to pursue external opportunities, with her last day set for March 3. Dr. Christine Zhou Xia Ping, Novo’s senior vice president and president of Region China, will assume the…
-
Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar version of Denmark-based Novo Nordisk A/S’s (NYSE: NVO) Tresiba (insulin degludec) has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication is adult type 2 diabetes. Drug ProfileInsulin degludec, a…
-
Gan & Lee Pharmaceuticals Doses First Patient in GZR4 Phase III Study for Diabetes
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed in a Phase III clinical study for GZR4, its Category 1 therapeutic biologic product. GZR4 is an investigational ultra-long-acting insulin designed for once-per-week subcutaneous injection to treat diabetes. Drug ProfileGZR4 aims to provide a convenient…
-
Sanofi’s Merilog Biosimilar Wins FDA Approval for Diabetes Treatment
•
The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis’ (EPA: SAN) Merilog, a biosimilar of Novo Nordisk’s (NYSE: NVO) NovoLog. Merilog, a rapid-acting insulin, is indicated for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. The approval includes both a 3 milliliter (mL) single-patient-use…
-
Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study, demonstrating the benefit of Mim8 in 70 children (aged 1-11 years old) with hemophilia A, both with and without inhibitors. The trial initially assessed once-weekly prophylaxis treatment with the investigational drug, offering participants the option…
-
Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care
•
Denmark’s Novo Nordisk (CPH: NOVO-B) reported this week that its global sales during 2024 reached DKK 290.403 billion (USD 42.1 billion), marking a 26% year-on-year (YOY) increase at constant exchange rates (CER). The strong performance was driven by growth across all business sectors, with notable increases in GLP-1 diabetes, Insulin,…
-
Novo Nordisk’s Amycretin Shows Promising Weight Loss Results in Phase Ib/IIa Study
•
Denmark – based pharmaceutical giant Novo Nordisk A / S (NYSE: NVO) has announced topline results from a Phase Ib / IIa study of its investigational drug amycretin, a unimolecular GLP – 1 and amylin receptor agonist. The study was designed to evaluate the safety, tolerability, pharmacokinetics, and proof –…
-
United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA
•
Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing for a biosimilar version of Novo Nordisk’s (NYSE: NVO) weight loss drug semaglutide (Ozempic/Wegovy) has been accepted for review by China’s National Medical Products Administration (NMPA). This marks a significant step towards introducing a more…
-
Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention’s expertise in BACH1 inhibition to…
-
Novo Nordisk’s Semaglutide 7.2 mg Shows Superior Weight Loss in Phase III Study
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced positive headline results from the Phase III STEP UP study, assessing the efficacy and safety of subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo. The study met its primary endpoint, demonstrating superior weight loss outcomes with the higher dose.…
-
Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative diabetes treatment, Rybelsus (semaglutide), in China. This marks a significant milestone for the company as it expands its presence in the Chinese market. Rybelsus: A First-in-Class TherapyRybelsus holds the distinction of being the world’s first…
-
Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes
•
Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease. The collaboration leverages Valo’s extensive human dataset and computation powered by artificial intelligence (AI) to accelerate the development of innovative therapies. Initial…
-
Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases
•
US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE: NVO) to jointly discover novel targets for the treatment of metabolic diseases. The collaboration is designed to identify and validate multiple innovative targets with strong human genetic evidence, paving the way for human-centric drug discovery…
-
Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA) of its biosimilar version of Denmark firm Novo Nordisk’s (NYSE: NVO) Victoza (liraglutide). Liraglutide: A Crucial Treatment for DiabetesLiraglutide, an analog of human…
-
Novo Nordisk’s Alhemo Receives FDA Approval for Hemophilia A and B Prophylaxis
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced that the US Food and Drug Administration (FDA) has granted marketing approval for its Alhemo (concizumab-mtci) injection. The drug is indicated as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years…
